Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Protein crystallization at the SER-CAT beamline at Argonne’s Advanced Photon Source proved key to the discovery of a new HIV vaccine candidate.

Primarily a grantmaking agency with an $8 billion budget, SAMHSA channels funds and training that the federal government ...

PrEP medications are not the same as vaccines and there is currently no available vaccine to prevent HIV. HIV remains a major public health concern, with 1·3 million new infections globally in ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research published in The Lancet medical journal. The drug lenacapavir passed a critical ...